Cargando…
Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease
PURPOSE OF REVIEW: The metabolic syndrome is a pathological state in which one of the key components is insulin resistance. A wide spectrum of body compartments is involved in its pathophysiology. Genetic and environmental factors such as diet and physical activity are both related to its etiology....
Autores principales: | Stols-Gonçalves, Daniela, Tristão, Luca Schiliró, Henneman, Peter, Nieuwdorp, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494784/ https://www.ncbi.nlm.nih.gov/pubmed/31044315 http://dx.doi.org/10.1007/s11892-019-1151-4 |
Ejemplares similares
-
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
por: Sunil, Bhuvana, et al.
Publicado: (2020) -
Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017) -
The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017) -
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017) -
Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)